Epidemiology and Infectious DiseasesEpidemiology and Infectious DiseasesЭпидемиология и инфекционные болезни3034-20073034-2015Eco-Vector4078910.17816/EID40789ArticlesСтатьиReview ArticleC. difficile toxins A and B from the clinician's viewpointТоксины А и В C. Difficile глазами клиницистаGyulazyanN. MГюлазянНаира Мартуновна

доктор мед. наук, проф. каф. инфекционных болезней

g.naira@rambler.ruBelayaO. FБелаяОльга Федоровна

доктор мед. наук, проф., зав. лаб. по изучению токсических и септических состояний

ofbelaya@mail.ruMalovV. AМаловВалерий Анатольевич

доктор мед. наук, проф. каф. инфекционных болезней

valmalov@list.ruPakS. GПакСергей Григорьевич

член-корр. РАМН, доктор мед. наук, проф., засл. зав. каф. инфекционных болезней

infection_mma@mail.ruYerevan State Medical University after Mkhitar HeratsiЕреванский государственный медицинский университет им. М. Гераци Министерства образования и науки АрменииI.M. Sechenov First Moscow State Medical UniversityПервый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России15122013186NO6 (2013)№6 (2013)424823072020Copyright ©; 2013, Eco-vectorCopyright ©; 2013, ООО "Эко-вектор"2013Eco-vectorООО "Эко-вектор"https://rjeid.com/1560-9529/article/view/40789

To date, C. difficile is considered as an etiological factor in pseudomembranous colitis and antibiotic-associated diarrhea as well as the main cause of nosocomial diarrhea spread mainly in economically developed countries. The complexity of laboratory and experimental studies of infection is what the microbe cannot be genetically manipulated. At the same time, the most of hospital and municipal laboratories have no the possibility to carry out research on detection C. difficile toxins, that limits the resource of real estimation of the spread of the disease in the Russian Federation.

На сегодняшний день C. difficile рассматривается как этиологический фактор псевдомембранозного колита и антибиотико-ассоцированной диареи, а также как ведущая причина внутрибольничных диарей распространенных преимущественно в экономически развитых странах. Сложность лабораторно-экспериментального исследования инфекции заключается в том, что микроб не поддается генетическим манипуляциям. Вместе с тем большинство госпитальных и муниципальных лабораторий не имеют возможности проводить исследования по обнаружению токсинов C. difficile, что ограничивает возможности истинной оценки распространения этого заболевания в РФ.

acute intestinal infectionspathogenic mechanisms of action of clostridial toxinspseudomembranous colitisantibiotic-associated diarrheadetection of clostridial toxinsострые кишечные инфекциипатогенетические механизмы действия токсинов клостридийпсевдомембранозный колитантибиотико-ассоцированная диареядетекция клостридиальных токсиновВертиев Ю.В. Бактериальные токсины: Биологическая сущность и происхождение. Журнал микробиологии, эпидемиологии и иммунобиологии. 1996; 3: 43-6.Гюлазян Н.М., Белая О.Ф., Белый Ю.Ф., Пак С.Г. Выявление маркеров токсинов клостридий при различных вариантах течения острых кишечных инфекций. Клиническая лабораторная диагностика. 2008; 3: 46-9.Малов В.А. Антибиотикоассоциированные диареи. Клиническая микробиология и антимикробная химиотерапия. 2002; 1: 22-32.Finlay B.B., Falkow S. Common themes in microbial pathogenicity revisited. Microbiol. Mol. Biol. Rev. 1997; 61: 136-69.Schmitt C.K., Meysick K.C., O’Brien A. Bacterial toxins: friends or foes? Emerg. Infect. Dis. 1999; 5 (2): 224-34.Brito G.A., Fujji J., Carneiro-Filho B.A et al. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J. Infect. Dis. 2002; 186: 1438-47.Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 2008; 46 (Suppl. 1): S12-8.Hatheway C. L., Toxigenic Clostridia. Clin. Microbiol. Rev. 1990; 66-98.Wistrom J., Norrby S.R., Myhre E.B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients; a prospective study. J. Antimicrob. Chemother. 2001; 47: 43-50.Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 2002; 34: 346-53.Wilkins T.D., Lyerly. D.M. Clostridium difficile testing: after 20 years, still challenging. J. Clin. Microbiol. 2003; 41: 531-4.Johnson S., Kent S.A., O’Leary K.J. et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med. 2001; 135: 434-8.Rupnik M., Kato N., Grabnar M., Kato H. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J. Clin. Microbiol. 2003; 41: 1118-25.Cohen S.H., Tang Y.J., Silva J. Jr. Analysis of the pathogenicity locus in Clostridium difficile strains. J. Infect. Dis. 2000; 181: 659-63.Mani N., Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. USA. 2001; 98: 5844-9.Onderdonk A.B., Lowe B.R., Bartlett J.G. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl. Environ. Microbiol. 1979; 38: 637-41.Just I., Hoffman F. et al. Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation. J. Biol. Chem. 1996; 271: 10 149-53.Tucker K.D., Wilkins T.D. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect. and Immun. 1991; 59: 73-8.Krivan H.C., Clark G.F., Smith D.F., Wilkins T.D. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gala1-3Galß1-4GlcNAc. Infect. and Immun. 1986; 53: 573-81.Smith J.A., Cooke D.L., Hyde S., Borriello S.P, Long R.G. Clostridium difficile toxin A binding to human intestinal epithelial cells. J. Med. Microbiol. 1997; 46: 953-8.Florin I., Thelestam M. Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts. Biochim. Biophys. Acta. 1983; 763: 383-92.Florin I., Thelestam M. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb. Pathog. 1986; 1: 373-85.Pfeifer G., Schirmer J., Leemhuis J. et al. Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J. Biol. Chem. 2003; 278: 44 535-41.Mitchell M.J., Laughon B.E., Lin S. Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect. and Immun. 1987; 55: 1610-5.Wedel N., Toselli P., Pothoulakis C. et al. Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp. Cell Res. 1983; 148: 413-22.Giesemann T., Egerer M., Jank T., Aktories K. Processing of Clostridium difficile toxins. J. Med. Microbiol. 2008; 57: 690-6.Jank T., GiesemmanT., Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology. 2007; 17 (4): 15S-22.Qa’Dan M., Ramsey M., Daniel J. et al. Clostridium difficile toxin B activates dual caspase-dependent and caspase-independent apoptosis in intoxicated cells. Cell. Microbiol. 2002. 4: 425-34.Souza M.H., Melo-Filho A.A., Rocha M.F. et al. The involvement of macrophage-derived tumour necrosis factor and lipooxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology. 1997; 91: 281-8.Shoshan M.C., Florin I., Thelestam M. Activation of cellular phospholipase A2 by Clostridium difficile toxin B. J. Cell. Biochem. 1993; 52: 116-24.Chen M.L., Pothoulakis C., LaMont J.T. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J. Biol. Chem. 2002; 277: 4247-54.Flegel W.A., Müller F., Däubener W. et al. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect. and Immun. 1991; 59: 3659-66.He D., Sougioultzis S., Hagen S. et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology. 2002; 122: 1048-57.Warny M., Keates A.C., Keates S. et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 2000; 105: 1147-56.Castagliuolo I., Kelly C.P., Qiu B.S. et al. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am. J. Physiol. 1997; 273: G333-41.He D., Hagen S.J., Pothoulakis C. et al. Clostridium difficile toxin A causes early damage to mitochondria in cultured cells. Gastroenterology. 2000; 119: 139-50.Savidge T.C., Pan W.H., Newman P. et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology. 2003; 125: 413-20.Siffert J.-C., Müller Ch.D., Dumont S. et al. CD14 expression by human mononuclear phagocytes is modulated by Clostridium difficile toxin B. Microb. Infect. 1999; 1: 1159-62.Samra Z., Talmor S., Bahar J. High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalized patients with gastrointestinal disease. Diagn. Microbiol. Infect. Dis. 2002; 43: 189-92.Lyerly D.M., Saum K.E., MacDonald D.K., Wilkins T.D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. and Immun. 1985; 47: 349-52.McDonald L.C., Killgore G.E., Thompson A. et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 2005; 353: 2433-41.Blanckaert K., Coignard B., Grandbastein B. et al. Update on Clostridium difficile infections. Rev. Med. Interne. 2008; 29 (3): 209-14.Loo V.G., Poirier L., Miller M.A. et al. A predominantly clonal multi institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005; 353: 2442-9.Warny M., Pepin J., Fang A. et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366: 1079-84.Fenner L., Widmer A.F., Goy G. et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J. Clin. Microbiol. 2008; 46 (1): 328-30.Sloan L.M., Duresko B.J., Gustafson D.R., Rosenblatt J.E. Comparison of real time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 2008; 46 (6): 1996-2001.Kim H., Jeong S.H., Kim M., Lee Y., Lee K. Detection of Clostridium difficile toxin A/B genes by multiplex real-time PCR for the diagnosis of C. difficile infection. J. Med. Microbiol. 2012; 61 (2): 274-7.Ylisiurua P., Koskela M., Vainio O., Tuokko H. Comparison of antigen and two molecular methods for the detection of Clostridium difficile toxins. Scand. J. Infect. Dis. 2013; 45 (1): 19-25.Snell H., Ramos M., Longo S., John M., Hussain Z. Performance of the TechLab C. DiFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 2004; 42 (10): 4863-5.